Comparing the Pharmacokinetics of Cagrilintide and Semaglutide Following Single Subcutaneous Doses of Different CagriSema Presentations, in a Crossover Manner in Adult Participants With Overweight or Obesity
Latest Information Update: 30 Sep 2025
At a glance
- Drugs Cagrilintide/semaglutide (Primary)
- Indications Obesity; Overweight
- Focus Pharmacokinetics
- Sponsors Novo Nordisk
Most Recent Events
- 17 Apr 2025 Status changed from recruiting to completed.
- 06 Jan 2025 Status changed from not yet recruiting to recruiting.
- 09 Dec 2024 New trial record